CONICET | Buscador de Institutos y Recursos Humanos

Here I describe our new pertussis vaccine candidate based onouter membrane vesicles (OMVs) derived from Bordetellapertussis. In comparison with the current acellular vaccines, our OMV-based vaccine contains a greater number of immunogens and conformationsclose to those found in the causal agent, favoring the protective capacity.Moreover, OMVs are ten times smaller in diameter than whole bacteria. This mayincrease the exposure to different cell types. We have demonstrated that ourformulations provide protection against different genotypic B. pertussis backgrounds inducing amixed Th1-Th17-Th2 profile and conferring a long-term protection in the murinemodel. Our vaccine formulation is attractive also from the economic point ofview. It is estimated that the final cost per dose wouldbe lower than that of the existing acellular vaccines based on several purifiedprotein immunogens one by one?a detail clearly impacting the final cost of thevaccine. Our developed OMV platform was also used for developing new vaccinesagainst other Bordetella species.